[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Special Offer on Therapy Class Reports from MP Advisors

MarketPublishers.com is happy to inform you about a lucrative opportunity to acquire 5 Therapy Class Reports at a special price.

A special price for this bundle of reports is USD 11,250, while its full price is USD 15,000.

The following publications are included in the offer:

Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain. One of main causes of disability in the USA, pain form one of key therapy areas. This market was worth USD 50 billion and continues growing. It is expected to demonstrate a CAGR of over 9.8 percent in the upcoming years. However, recent expiry of the Cymbalta’s patent hit the marketplace and expiry of Lyrica in the near future will impact the market as well. The research report offers in-depth examination of the pain management market worldwide covering drug pipeline, market players, …

New Phase of Mab biosimilar knocks the door Biosimilar Oppurtunities In Japan. The Japanese pharmaceutical market faster than the USA adapts to the use of biosimilars. The launch of Remicade biosimilar in H2 2014 in demonstrated changing regulatory environment of the local market. The research study provides in-depth examination of opportunities existing in the field of biosimilars in Japan. It uncovers requirements for regulatory approval, discusses a reimbursement scenario and delves deep into the market dynamics. The report scrutinizes the competitive landscape and profiles market players, their latest activities in the marketplace, …

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease. With proteasome inhibitors and immunomodulatory drugs being used for treatment of multiple myeloma over the last ten years, new drugs (e.g. POMALYST) have recently appeared on the stage thus offering new treatment options The research report provides a though overview of multiple myeloma, diagnostic criteria and approaches. The study delves into diagnostic tools for the disease, discusses market opportunities in this space and reviews M&A activities. It casts light on current therapies and unveils novel targets, besides reviewing clinical milestones …

Dietary Supplements: World of Opportunities In the Indian Healthcare Market. The market for nutraceuticals has demonstrated swift growth due to a number of factors, such as low regulatory hurdles, high demand from consumers and product innovations. China and India are leading players in the Asia-Pacific marketplace. India is one more promising market in the region. The research report offers an up-close look at the global market for dietary supplements, with a special focus made on the nutraceuticals segment. The study contains regulatory guidelines; explores key therapeutics areas set to drive the market growth, …

Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure. The pharma industry grows at a fast pace, with sales expected to surpass the USD 1 trillion mark by 2020. Stem cell therapy/regenerative medicine represent one of the most lucrative segments of the market. The research report provides an in-depth insight into field of regenerative medicine/stem cell based therapies. It contains valuable data on marketed cell based/stem cell products. The study investigates progress and challenges existing in the space, highlights upcoming milestones, sheds light on latest events in the marketplace …

For more details, please, contact Alison, our Sales Manager. E-mail: [email protected]. Tel.: +44 20 8123 2220.

Publications found: 5
Sort by:

New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan

US$ 4,000.00

... players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei), Global Multinationals (Pfizer, Sandoz) and some rising star JP local companies (Yoshindo, Gene Techno Science, Sanwa Kagaku ...

January 2015 65 pages

Dietary Supplements: World of Opportunities In the Indian Healthcare Market

US$ 2,000.00

... new opportunities or geography expansion in the functional food, beverage, and supplement (FBS) market. Nutraceutical is divided into three segments – dietary supplements, functional foods and functional beverages. Globally, Nutraceuticals ...

January 2015 62 pages

Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure

US$ 3,000.00

... with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected ... the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a ...

January 2015 98 pages

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

US$ 3,000.00

... Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib ...

January 2015 82 pages

Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain

US$ 3,000.00

... cyclooxygenase (COX) inhibitors, amine reuptake inhibitors and anticonvulsants, ... acute and chronic moderate to severe pain. Globally, pain is one of the ... formulations can be better understood from FDA’s non-approval of oxycontin generics in 2013. The revised labeling with abuse deterrence has protected Purdue ...

January 2015 65 pages

Filters

Search

Categories

1
1
1
1
1

Publishers

5

Regions

3
1
1

Price

Date

Pages

Offers

5